Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
TORONTO and CAMBRIDGE, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for...
-
TORONTO and CAMBRIDGE, Mass., Oct. 11, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for...
-
Presentation highlights the use of ProMIS’ proprietary discovery platform to identify novel therapeutic targets on misfolded proteins in multiple neurodegenerative diseases TORONTO and CAMBRIDGE,...
-
TORONTO, ONTARIO and CAMBRIDGE, MA , Sept. 21, 2017 (GLOBE NEWSWIRE) -- ERN UK...
-
TORONTO and CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- ERN UK...
-
TORONTO and CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- ERN UK...
-
TORONTO, Aug. 28, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX:PMN) (OTCPK:ARFX.F) (DB:23J) is pleased to announce that, further to its news releases dated...
-
TORONTO and CAMBRIDGE, Mass., Aug. 11, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for...
-
TORONTO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX:PMN) (OTCPK:ARFX.F) (DB:23J) is pleased to announce that, further to its news releases dated...